Login / Signup
Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis.
Seok Hyeon Song
Se Joon Woo
Published in:
Ocular immunology and inflammation (2024)
Switching from adalimumab originator to SB5 for NIU does not result in clinically significant differences in treatment efficacy and safety.
Keyphrases
</>
juvenile idiopathic arthritis
rheumatoid arthritis
hidradenitis suppurativa
ulcerative colitis
disease activity
ankylosing spondylitis
systemic lupus erythematosus
replacement therapy